<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243137</url>
  </required_header>
  <id_info>
    <org_study_id>2012-ECCLIPSE-01</org_study_id>
    <secondary_id>2012-001702-20</secondary_id>
    <nct_id>NCT02243137</nct_id>
  </id_info>
  <brief_title>Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate</brief_title>
  <acronym>ECCLIPSE</acronym>
  <official_title>Effects of Combinated Administration of Lysine Acetylsalicylate Versus Prasugrel and Aspirin on Platelet Aggregation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Vivas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St Carlos Hospital, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Investigacion Interhospitalaria Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I clinical trial in healthy volunteers comparing the effect of lysine&#xD;
      acetylsalicylate or aspirin on platelet function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. SUMMARY 1.1. Type of trial Phase I clinical trial in healthy volunteers and marketed drugs&#xD;
      1.2. Identification of the promoter (correspondence to) Dr. David Vivas Balcones Cardiology&#xD;
      Department Hospital Clínico San Carlos C/Prof Martín Lagos SN 28040 Madrid Phone: +34 91 330&#xD;
      31 49 Fax: +34 913303142 Email: dvivas@secardiologia.es 1.3. Clinical trial title Effect of&#xD;
      combined administration of prasugrel and lysine acetylsalicylate intravenously versus&#xD;
      prasugrel and aspirin on platelet aggregation in healthy volunteers (ECCLIPSE trial).&#xD;
&#xD;
      1.4. Protocol code Nº EudraCT: 2012-001702-20 Code: 2012-ECCLIPSE-01 Version: V3 Date:&#xD;
      13/04/2012&#xD;
&#xD;
      1.5. Project principal investigator Dr. David Vivas Balcones Cardiology Department Hospital&#xD;
      Clínico San Carlos C/Prof Martín Lagos SN 28040 Madrid Phone: +34 91 330 31 49 Fax: +34&#xD;
      913303142 Email: dvivas@secardiologia.es 1.6. Centers Investigators&#xD;
&#xD;
      San Carlos University Hospital (Madrid). Within the following services and researchers are&#xD;
      involved:&#xD;
&#xD;
      Cardiology Department Hospital Clínico San Carlos C/Prof Martín Lagos SN 28040 Madrid&#xD;
      Teléfono: +34 91 330 31 49 Fax: +34 913303142 Project principal investigator and Promoter:&#xD;
      Dr. David Vivas Balcones Co-Investigators: Dr. Agustín Martín, Dr. Isidre Vilacosta, Dr. Iván&#xD;
      Núñez-Gil y Dr. Carlos Macaya&#xD;
&#xD;
      Platelet function laboratory Cardiology Department Hospital Clínico San Carlos C/Prof Martín&#xD;
      Lagos SN 28040 Madrid Phone: +34 913307260 Fax: +34 913303142 Co-Investigators: Dr. Antonio&#xD;
      Fernández-Ortiz, Esther Bernardo y María Aranzazu Ortega Pozzi&#xD;
&#xD;
      Clinical Trials Unit (CEIC) Biomedical Research Foundation Hospital Clínico San Carlos C/&#xD;
      Prof. Martín Lagos S/N 28040 Madrid Phone: + 34 913303793 Fax: +34 913303515 Co-Investigator:&#xD;
      Dra. Saioa Alonso&#xD;
&#xD;
      Clinical Research Ethics Committee The Clinical Research Ethics Committee (CEIC) charged with&#xD;
      assessing the project will be the CEIC of the San Carlos University Hospital.&#xD;
&#xD;
      1.7. Responsible for Monitoring: MEDITRIALS 1.8. Experimental and control drug • Experimental&#xD;
      group: Loading dose (LD) of intravenous lysine acetylsalicylate 450 mg and prasugrel 60 mg&#xD;
      orally.&#xD;
&#xD;
      • Control group: Loading dose (LD) of aspirin 300 mg orally and prasugrel 60 mg orally. Being&#xD;
      a crossover study, subjects will receive both treatment arms in the two treatment periods&#xD;
      with a gap of 15 days (washout period) between the two administrations.&#xD;
&#xD;
      1.9. Study endpoints Primary endpoint To compare the inhibition of platelet aggregation (IPA)&#xD;
      at 30 minutes after administration of prasugrel loading dose in association with intravenous&#xD;
      lysine acetylsalicylate versus prasugrel plus aspirin.&#xD;
&#xD;
      Secundary endpoints To compare the inhibition of platelet aggregation (IPA) at 0 (baseline),&#xD;
      1, 4 and 24 hours after the administration of both treatment groups.&#xD;
&#xD;
      To compare the inhibition of platelet reactivity (IPR) throughout the time period in both&#xD;
      treatment groups.&#xD;
&#xD;
      To evaluate the safety of the treatment administered.&#xD;
&#xD;
      1.10. Study design The ECCLIPSE study is a phase I, randomized, single center, open,&#xD;
      two-period crossover trial in each of which subjects receive a single dose of certain drugs&#xD;
      in each treatment group.&#xD;
&#xD;
      1.11. Pathology study None. 1.12. Population and sample size The study population will be&#xD;
      healthy volunteers (total 30 subjects). This is a pharmacodynamic study, with subsequent&#xD;
      extrapolation of findings to patients with acute coronary syndrome 1.13. Duration of&#xD;
      treatment In each period of treatment, subjects will received a single dose of drugs&#xD;
      determined in each treatment arm and the analysis of the parameters under study will be&#xD;
      processed over the next 24 hours. After the two weeks washout period, subjects will receive&#xD;
      the other study drug regimen in a single dose and it will take place the analysis within 24&#xD;
      hours of the parameters studied.&#xD;
&#xD;
      1.14. Primary variable Inhibition of platelet aggregation measured by light transmission&#xD;
      aggregometry at 30 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of platelet aggregation</measure>
    <time_frame>at 30 minutes</time_frame>
    <description>measured by light transmission aggregometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of platelet aggregation</measure>
    <time_frame>baseline, 1 h, 4 h and 34 h</time_frame>
    <description>measured by light transmission aggregometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of platelet reactivity</measure>
    <time_frame>baseline, 1 h, 4 h and 34 h</time_frame>
    <description>by the platelet reactivity index (PRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>baseline, 30 min, 1 h, 4 h, and 24 h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Adverse Effect of Antithrombotic Drugs</condition>
  <arm_group>
    <arm_group_label>prasugrel and acetylsalicylic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose of prasugrel 60 mg orally and 300 mg acetylsalicylic acid orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lysine acetylsalicylate and prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of prasugrel 60 mg oral and lysine acetylsalicylate 450 mg intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <description>Administration: one dose of Acetylsalicylic Acid (300mg)</description>
    <arm_group_label>prasugrel and acetylsalicylic</arm_group_label>
    <other_name>Adiro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>Administration: one loading dose (60mg)</description>
    <arm_group_label>lysine acetylsalicylate and prasugrel</arm_group_label>
    <arm_group_label>prasugrel and acetylsalicylic</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lysine acetylsalicylate</intervention_name>
    <description>Administration: one dose (450mg iv)</description>
    <arm_group_label>lysine acetylsalicylate and prasugrel</arm_group_label>
    <other_name>Inyesprin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60 years.&#xD;
&#xD;
          -  BMI&gt; 19kg/m2 and &lt;29kg/m2.&#xD;
&#xD;
          -  Women of childbearing potential who are committed to use a medically effective&#xD;
             contraception during their participation in the study, except hormonal contraceptives.&#xD;
&#xD;
          -  Percentage of inhibition of platelet aggregation after stimulation with high basal 20&#xD;
             mM ADP and arachidonic acid 1.5 mM&gt; 70%.&#xD;
&#xD;
          -  No clinically significant deviation on physical examination, ECG or laboratory values&#xD;
             in laboratory tests.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Infection with Hepatitis B or C, or HIV&#xD;
&#xD;
          -  Known drug allergies&#xD;
&#xD;
          -  Family history of blood disorders or coagulation.&#xD;
&#xD;
          -  History of disease that alters the absorption, metabolism or excretion of drugs,&#xD;
             including jaundice.&#xD;
&#xD;
          -  Personal history of bleeding and / or blood dyscrasias (especially hemophilia,&#xD;
             hypoprothrombinemia), including vascular malformations reasonable suspicion.&#xD;
&#xD;
          -  History of any medically relevant condition&#xD;
&#xD;
          -  Background of major surgery in the last 3 months&#xD;
&#xD;
          -  Prescription of chronic medication in the 14 days prior to study participation.&#xD;
&#xD;
          -  Participation in another study involving the administration of an investigational&#xD;
             product in the last 4 months or a product already on the market in the last three&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Vivas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Carlos University Hospital, Madrid Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>June 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2014</study_first_posted>
  <last_update_submitted>September 15, 2014</last_update_submitted>
  <last_update_submitted_qc>September 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Investigacion Interhospitalaria Cardiovascular</investigator_affiliation>
    <investigator_full_name>David Vivas</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Acetylsalicylic acid lysinate</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

